PTC Therapeutics is a biopharmaceutical company focused on the discovery and development of orally administered, small molecule drugs that target post-transcriptional control processes. The company's current clinical pipeline targets genetic disorders, oncology and infectious diseases. PTC's lead product, Translarna (ataluren), is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.